Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; maize starch; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

nrc nutrition pty ltd - passiflora incarnata, quantity: 25 mg (equivalent: passiflora incarnata, qty 1.25 g); matricaria chamomilla, quantity: 112.5 mg (equivalent: matricaria chamomilla, qty 900 mg); withania somnifera, quantity: 112.5 mg (equivalent: withania somnifera, qty 2.25 g); lavender oil, quantity: 40 mg; crocus sativus, quantity: 2.997 mg (equivalent: crocus sativus, qty 9.99 mg) - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; ascorbyl palmitate; microcrystalline cellulose; maltodextrin; hypromellose; potable water; dextrin - traditionally used in western herbal medicine to adaptogen/help body adapt to stress ; traditionally used in western herbal medicine to help maintain/support emotional wellbeing ; traditionally used in western herbal medicine to soothe/calm nerves ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in western herbal medicine to calmative/nervous system relaxant ; traditionally used in western herbal medicine to nervine/support nervous system ; traditionally used in western herbal medicine to decrease/reduce/relieve sleeplessness ; traditionally used in western herbal medicine to decrease/reduce/relieve disturbed/restless sleep ; traditionally used in western herbal medicine to enhance/promote/increase healthy sleep patterns ; traditionally used in western herbal medicine to maintain/support healthy sleeping patterns

Australia - English - Department of Health (Therapeutic Goods Administration)

nrc nutrition pty ltd - salvia officinalis, quantity: 90 mg (equivalent: salvia officinalis, qty 900 mg; equivalent: thujone, qty 3.6 mg); valeriana officinalis, quantity: 175 mg (equivalent: valeriana officinalis, qty 1.75 g); humulus lupulus, quantity: 94.67 mg (equivalent: humulus lupulus, qty 710 mg); ziziphus jujuba var. spinosa, quantity: 66.67 mg (equivalent: ziziphus jujuba var. spinosa, qty 2 g) - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; microcrystalline cellulose; maltodextrin; ascorbyl palmitate; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - traditionally used in western herbal medicine to soporific/induces sleep ; traditionally used in western herbal medicine to decrease/reduce time to fall asleep ; traditionally used in western herbal medicine to decrease/reduce/relieve disturbed/restless sleep ; traditionally used in western herbal medicine to enhance/promote/increase healthy sleep patterns ; traditionally used in western herbal medicine to helps decrease/reduce/relieve night sweats associated with menopause ; maintain/support oestrogen hormone levels ; traditionally used in western herbal medicine to maintain/support healthy reproductive hormones

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics pm pty ltd - ripretinib, quantity: 50 mg - tablet - excipient ingredients: silicon dioxide; microcrystalline cellulose; hypromellose acetate succinate; crospovidone; magnesium stearate; lactose monohydrate - qinlock is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumours (gist) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - teclistamab, quantity: 30 mg - injection, solution - excipient ingredients: glacial acetic acid; sucrose; disodium edetate; sodium acetate trihydrate; polysorbate 20; water for injections - tecvayli as monotherapy has provisional approval in australia and is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 monoclonal antibody.,the decision to approve this indication has been made on the basis of the overall response rate in a single arm study. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - teclistamab, quantity: 153 mg - injection, solution - excipient ingredients: polysorbate 20; sodium acetate trihydrate; glacial acetic acid; sucrose; water for injections; disodium edetate - tecvayli as monotherapy has provisional approval in australia and is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 monoclonal antibody.,the decision to approve this indication has been made on the basis of the overall response rate in a single arm study. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vet med ip pty ltd - ivermectin - oral tablet - ivermectin anthelmintic active 68.0 ug/tb - parasiticides - dog - up to 11kg - heartworm - prevention of | to prevent heartworm

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tylosin tartrate; trenbolone acetate; oestradiol - parenteral implant, device - tylosin tartrate antibiotic active 29.0 mg/im; trenbolone acetate steroid-anabolic active 140.0 mg/im; oestradiol steroid-estrogen active 28.0 mg/im - nutrition & metabolism - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - abscess | promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - copper oxide rods - oral capsule - copper oxide rods mineral-copper active 10.0 g/bullet - nutrition & metabolism - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - copper deficiency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - tryptophan; magnesium as magnesium oxide; pron8ure; vitamin b3 = nicotinamide; vitamin b2 = riboflavin; vitamin b1 hydrochloride = thiamine hydrochloride; vitamin b6 hydrochloride = pyridoxine hydrochloride - oral powder, pre-mix - tryptophan amino acid-tryptophan active 33.3 g/kg; magnesium as magnesium oxide mineral-magnesium active 285.0 g/kg; pron8ure active 20.0 b cfu/kg; vitamin b3 = nicotinamide vitamin-b3 active 3.3 g/kg; vitamin b2 = riboflavin vitamin-b2 active 16.7 g/kg; vitamin b1 hydrochloride = thiamine hydrochloride vitamin-b1 active 66.6 g/kg; vitamin b6 hydrochloride = pyridoxine hydrochloride vitamin-b6 active 8.3 g/kg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - high grain rations | improve digestive efficacy | mood stabiliser | re-establishment of gut microflora | stress | digestive aid | feed conversion efficacy | following antibiotic use | post-antibiotic therapy